TerrAscend (TSNDF) Share-based Compensation (2021 - 2026)
TerrAscend's (TSNDF) quarterly Share-based Compensation came in at $885000.0 in Q1 2026, down 41.55% year-on-year from $1.5 million in Q1 2025, and down 76.27% on a QoQ basis from $3.7 million in Q4 2025.
TerrAscend (TSNDF) Share-based Compensation (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has 6 years of Share-based Compensation data on file, last reported at $885000.0 in Q1 2026.
- On a quarterly basis, Share-based Compensation fell 41.55% year-over-year to $885000.0 in Q1 2026; TTM through Mar 2026 was $8.1 million, a 12.34% increase from a year earlier, with the FY2025 full-year figure at $5.0 million, down 48.41% from the prior year.
- Share-based Compensation for Q1 2026 stood at $885000.0, down from $3.7 million in the prior quarter.
- Over the last five years, Share-based Compensation for TSNDF reached as high as $39.7 million in Q3 2022 and fell as low as $885000.0 in Q1 2026.
- Historically, Share-based Compensation has averaged $8.4 million across 5 years, with a median of $3.4 million in 2022.
- Across the five-year window, Share-based Compensation jumped 977.66% in 2022 and sank 79.35% in 2023, its largest moves.
- Year by year, Share-based Compensation stood at $1.6 million in 2022, then jumped by 36.63% to $2.2 million in 2023, then decreased by 11.26% to $2.0 million in 2024, then surged by 87.76% to $3.7 million in 2025, then tumbled by 76.27% to $885000.0 in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $885000.0 in Q1 2026, $3.7 million in Q4 2025, and $3.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | TerrAscend | 160.44 Mn | 162.98 Mn | 34.60 Mn | 885,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 885,000.00 |
| Mar 31, 2026 | 885,000.00 |
| Dec 31, 2025 | 3.73 Mn |
| Dec 31, 2025 | 3.73 Mn |
| Sep 30, 2025 | 3.04 Mn |
| Sep 30, 2025 | 3.04 Mn |
| Jun 30, 2025 | 3.83 Mn |
| Jun 30, 2025 | 3.83 Mn |
| Mar 31, 2025 | 1.51 Mn |
| Mar 31, 2025 | 1.51 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Sep 30, 2024 | 6.68 Mn |
| Sep 30, 2024 | 6.68 Mn |
| Jun 30, 2024 | 7.66 Mn |
| Jun 30, 2024 | 7.66 Mn |
| Mar 31, 2024 | 1.49 Mn |
| Mar 31, 2024 | 1.49 Mn |
| Dec 31, 2023 | 2.24 Mn |
| Dec 31, 2023 | 2.24 Mn |